BCTX logo

BriaCell Therapeutics Corp. (BCTX)

$3.51

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BCTX

Market cap

$30227369

EPS

-30.98

P/E ratio

--

Price to sales

--

Dividend yield

--

Beta

1.256738

Price on BCTX

Previous close

$3.30

Today's open

$3.27

Day's range

$3.27 - $3.59

52 week range

$2.60 - $13.09

Profile about BCTX

CEO

William V. Williams

Employees

22

Headquarters

West Vancouver, BC

Exchange

NASDAQ Capital Market

Shares outstanding

8732381

Issue type

Common Stock

BCTX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BCTX

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced preclinical findings from four posters at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

news source

GlobeNewsWire • Nov 6, 2026

news preview

BriaCell Awarded 2026 “Immunotherapy Solution of the Year” By BioTech Breakthrough

LOS ANGELES, Nov. 05, 2026 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe, announced today that it has awarded BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, for “Immunotherapy Solution of the Year” in its sixth annual BioTech Breakthrough Awards program. BriaCell's lead treatment, Bria-IMT™, is a targeted cell-based immunotherapy for the treatment of metastatic breast cancer.

news source

GlobeNewsWire • Nov 5, 2026

news preview

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026

Four presentations highlight BriaCell's Bria-OTS+™ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programs In vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer models BriaPro data describes BP-80 tolerability in nonhuman primates and engineered CD80 constructs with enhanced PD-L1 binding PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced four preclinical research presentations at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations cover BriaCell's personalized off-the-shelf immunotherapy platform, Bria-OTS+, and three BriaPro research programs: BP-80, a soluble CD80-Fc fusion protein; TILsRx-001, a tumor-targeted CD80-based checkpoint inhibitor; and engineered CD80 variants with altered immune receptor binding.

news source

GlobeNewsWire • Nov 3, 2026

news preview

BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer (“MBC”) treated with immune based therapies including the BriaCell regimen at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place October 23-27, 2026 in Madrid, Spain. The data shown is pooled from several studies including BriaCell's Phase 1/2 Bria-IMT study.

news source

GlobeNewsWire • Oct 23, 2026

news preview

BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations will feature BriaCell's personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro's research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.

news source

GlobeNewsWire • Oct 6, 2026

news preview

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces that the independent Data Safety Monitoring Board (DSMB) has issued its seventh consecutive positive recommendation following review of clinical data from BriaCell's pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor (CPI) in patients with metastatic breast cancer (NCT06072612).

news source

GlobeNewsWire • Sep 14, 2026

news preview

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612 ).

news source

GlobeNewsWire • Sep 8, 2026

news preview

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

Cell-based immunotherapy program is designed to harness patients' own immune systems Bria-MEL+ is a personalized, off-the-shelf immunotherapy vaccine candidate intended to enable patient specific treatment without individualized manufacturing Program builds on BriaCell's experience in metastatic breast cancer and prostate cancer, further expanding its therapeutic vaccine platform Melanoma remains a significant unmet medical need, with approximately 112,000 new cases and 8,510 deaths expected in the US in 2026 PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a key genetic engineering milestone, advancing the program toward clinical development. Bria-MEL+ is a cell-based therapeutic cancer vaccine designed to harness a patient's own immune system to combat melanoma.

news source

GlobeNewsWire • Aug 24, 2026

news preview

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell's next generation personalized immunotherapy for prostate cancer and incorporates additional immune activating components designed to enhance clinical efficacy Bria-PROS+ program previously awarded $2 million grant from the US National Cancer Institute PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for Bria-PROS+ and issued a Study May Proceed letter, clearing the way for clinical evaluation of Bria-PROS+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for prostate cancer. “We are pleased to announce FDA clearance of the IND for Bria-PROS+, our next-generation personalized immunotherapy for prostate cancer,” stated Dr. William V.

news source

GlobeNewsWire • Aug 5, 2026

news preview

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that the Odette Cancer Centre at Sunnybrook Health Sciences Centre, a leading cancer center in Toronto, Ontario, Canada, has joined BriaCell's ongoing pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier:  NCT06072612 ).

news source

GlobeNewsWire • Jul 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in BriaCell Therapeutics Corp.

Open an M1 investment account to buy and sell BriaCell Therapeutics Corp. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BCTX on M1